Chronic constipation
Conditions
Interventions
None listed
Sponsors
TSUJINAKA HOSPITAL KASHIWANOHA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with chronic constipation and assessed as inadequate responders to the existing therapy (magnesium oxide, etc.) 2) Patients with 20 years or older at baseline 3) Patients receiving Movicol during the investigation period 4) Patients receiving the existing therapy (magnesium oxide, etc.) from more than 2 weeks before administration of Movicol
Exclusion criteria
Exclusion criteria: 1) Patients who are suspected constipation due to organic disease 2) Patients with a history of hypersensitivity to any ingredients of Movicol 3) Patients who are confirmed or suspected intestinal obstruction, intestinal perforation, or severe inflammatory bowel disease (ulcerative colitis, Crohn's disease, toxic megacolon, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of CSS total score between baseline and at Week 4 of administration | — |
Secondary
| Measure | Time frame |
|---|---|
| JPAC-QOL score CSS total score (of each evaluation time point from baseline to Week 8) CSS sub score (at each evaluation time point from baseline to Week 8) Bristol Stool Form Scale | — |
Countries
Japan
Contacts
Public ContactTakafumi Maeda
TSUJINAKA HOSPITAL KASHIWANOHA Coloprocrology
Outcome results
None listed